Beacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene Therapies
Beacon Therapeutics, a leading ophthalmic gene therapy company that acquired UF startup AGTC to save and restore the vision of patients with blinding retinal diseases, announced it has raised $170 million in Series B funding.
Ascend Acquires Beacon Gene Therapy Manufacturing Site
Ascend Advanced Therapies, a gene therapy development partner, has purchased Beacon Therapeutics’ contract, manufacturing, and controls team—along with the company's site, previously owned by UF Innovate | Accelerate graduate AGTC, located in Alachua, FL—a town considered to be a “biotech hub” in the state. The acquisition introduces a good manufacturing practice (GMP) plant into the fold, along with process and analytical development capabilities.
AGTC Announces Positive Three-Month Interim Results From Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa
UF startup and UF Innovate | Sid Martin Biotech graduate Applied Genetic Technologies Corporation (AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today reported positive three-month interim data from its ongoing Phase 2 Skyline trial of AGTC-501, a recombinant AAV viral vector-based gene therapy targeting mutations in the RPGR gene in patients with X-linked retinitis pigmentosa (XLRP).
Mobile Eye Care Clinic Offering Free Exams, Glasses to Boston Students
Many people have put off medical care during the pandemic and that includes eye exams for children. But on Tuesday, the doctor -- funded by UF startup AGTC -- went to the students at one Boston school.
AGTC-501 Gene Therapy Offers Vision Gains for X-Linked RP
AGTC-501 (Applied Genetic Technologies Corporation), a novel gene therapy in development for the potential treatment of X-linked retinitis pigmentosa (RP), showed an acceptable safety profile and visual function improvements when administered in the study’s higher dose groups, according to Robert A. Sisk, MD, FACS, from the Cincinnati Eye Institute in Ohio.
Applied Genetic Technologies exceeds enrollment target for SKYLINE trial of AGTC-501
Applied Genetic Technologies Corp. announced it had exceeded the enrollment target in the Company’s SKYLINE trial of AGTC-501, a recombinant AAV vector-based gene therapy developed for the treatment of X-linked retinitis pigmentosa (XLRP).
University of Florida Innovators Honored at 4th Annual Standing InnOvation Event
On a sunny and fresh fall afternoon, UF Innovate | Tech Licensing hosted its annual event to recognize top innovations stemming out of the University of Florida. More than 150 innovators and entrepreneurs attended the in-person event, and around 40 joined the livestream to celebrate their achievements in fiscal year 2021.
AGTC: The New Leader in Ocular Gene Therapy With Sue Washer
Sue Washer, president and CEO of Applied Genetic Technologies Corporation (AGTC), discusses ocular gene therapy with the Eye Care Insider podcast host Joshua Mali, MD.
AGTC Is Excited To Announce Seasoned Healthcare Financial and Operations Executive Jonathan I. Lieber As Their New Chief Financial Officer
UF startup and UF Innovate | Sid Martin Biotech graduate Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, announced Jonathan I. Lieber as their new Chief Financial Officer.
Greater Gift, AGTC, and 2020 On-Site Partner To Honor & Celebrate Clinical Trial Participants and Provide Eye Exams to Underserved Children in the Local Community
Greater Gift of Winston Salem, a non-profit that celebrates participation in clinical trials, announced a partnership with UF startup and UF Innovate | Sid Martin Biotech graduate Applied Genetic Technologies Corporation (AGTC), a biotechnology company developing genetic therapies for the treatment of rare inherited retinal diseases (IRDs), and mobile vision provider 2020 On-site, a company involved in IRD clinical research and provides complimentary eye exams and facilitates the delivery of eyeglasses to students in need.
